Negative Regulation of Leucocyte Functions by CD33-related Siglecs
Overview
Authors
Affiliations
The siglecs (sialic acid-binding Ig-like lectins) are a family of transmembrane receptors expressed in the haemopoietic, immune and nervous systems. The CD33-related siglecs are a distinct subset mostly expressed in the innate immune system where they can function as inhibitory receptors by suppressing the signalling mediated by receptors coupled with ITAMs (immunoreceptor tyrosine-based activation motifs). CD33-related siglecs contain ITIMs (immunoreceptor tyrosine-based inhibitory motifs) that recruit and activate SHP-1 [SH2 (Src homology 2) domain-containing phosphatase-1] and SHP-2. In addition, the ITIMs of CD33-related siglecs can suppress siglec-dependent adhesion of sialylated ligands and mediate endocytosis. Siglec-H is a recently characterized murine CD33-related endocytic receptor that lacks intrinsic tyrosine-based signalling motifs and is expressed selectively on PDCs (plasmacytoid dendritic cells). Siglec-H depends on DAP12 (DNAX-activating protein of 12 kDa) for surface expression and cross-linking with anti-siglec-H antibodies can selectively inhibit interferon-alpha production by PDCs following TLR9 (Toll-like receptor 9) ligation. Thus CD33-related siglecs are able to mediate diverse inhibitory functions of leucocytes in the innate immune system via both ITIM-dependent and -independent pathways.
Liu C, Zhu J, Mi Y, Jin T J Neuroinflammation. 2022; 19(1):298.
PMID: 36510261 PMC: 9743681. DOI: 10.1186/s12974-022-02663-z.
Lubbers J, Eveline Li R, Gorki F, Bruijns S, Gallagher A, Kalay H Immunother Adv. 2022; 1(1):ltab012.
PMID: 35919745 PMC: 9327115. DOI: 10.1093/immadv/ltab012.
Yang J, Ma W, Wu Y, Zhou H, Song S, Cao Y Microbiol Spectr. 2021; 9(3):e0039921.
PMID: 34878295 PMC: 8653822. DOI: 10.1128/spectrum.00399-21.
Karmakar J, Mukherjee K, Mandal C Front Immunol. 2021; 12:758588.
PMID: 34804046 PMC: 8595208. DOI: 10.3389/fimmu.2021.758588.
Jarahian M, Marofi F, Maashi M, Ghaebi M, Khezri A, Berger M Cancers (Basel). 2021; 13(20).
PMID: 34680351 PMC: 8534074. DOI: 10.3390/cancers13205203.